Lupkynis Adoption Lupkynis is the first FDA-approved oral therapy for active lupus nephritis, signaling a focus on a high-need autoimmune market and potential expansion opportunities with nephrology and rheumatology care teams.

Leadership Change A recent leadership overhaul with Kevin Tang as CEO and new executive team members may drive strategic pivots, potential partnerships, or M&A activity to accelerate pipeline progress and commercial reach.

Bioscience Pipeline The development of AUR200 (BAFF and APRIL dual inhibitor) and aritinercept indicates a broadened portfolio in autoimmune targets, offering cross-sell potential to clinicians treating related autoimmune conditions.

Financial runway Revenue in the hundreds of millions with a substantial funding cushion positions Aurinia to invest in field force expansion, clinical trials, and payer market access strategies to support broader adoption.

Strategic Partnerships Active participation in major rheumatology forums and ongoing data presentations at EULAR suggest opportunities to align with academic centers, opinion leaders, and payer stakeholders for expanded access and evidence generation.